Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Heyndrickxia coagulans + Fructooligosaccharides (FOS) + Maltodextrin & Type 1 diabetes (T1D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

IRCT20180310039020N1 - Heyndrickxia coagulans GBI-30 - 6086 + Fructooligosaccharides (FOS) + Maltodextrin & Type 1 diabetes (T1D)

This placebo-controlled, double-blind, randomized clinical trial revealed that the eight-week synbiotic supplementation in patients with Type 1 Diabetes (T1D) may effectively improve fasting blood glucose (FBG), hemoglobin A1c (HbA1c), insulin levels, high-sensitivity C-reactive protein (hs-CRP), and total antioxidant capacity (TAC) (1).

References

(1) Javid et al. 2020 Diabetes Metab Syndr Obes 13: 607-617

see also:
[Synbiotics & Type 1 Diabetes (T1D)](brain://oroKTJObnk69841Pvh03dA/SynbioticsType1Diabe…

References (Sources)

The effects of synbiotic supplementation on glycemic status, lipid profile, and biomarkers of oxidative stress in type 1 diabetic patients. A placebo-controlled, double-blind, randomized clinical trial
Javid et al. 2020 Diabetes Metab Syndr Obes 13: 607-617

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!